Early real-world utilization of ADA-adaz (Hyrimoz) in the United States

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Adalimumab (ADA)-adaz (Hyrimoz®; Sandoz, Inc.) became available in the United States (US) in July 2023. This study assessed real-world ADA-adaz adoption experience by describing characteristics and treatment history of patients initiating ADA-adaz in the months following its US availability and preliminarily assessing persistence and adherence to ADA-adaz. A retrospective cohort study using open and closed claims from Komodo Research Data (01/2016-05/2024) was conducted. The index date was the first ADA-adaz prescription after July 2023. For the demographics and clinical assessment subgroup, ≥12 months of continuous data availability pre-index (baseline period) was required. For the persistence and adherence assessment subgroup, ≥3 months of continuous health plan enrollment post-index (study period) was required. Persistence was measured as time from index to the earlier of switch or discontinuation (45-day gap). Adherence was measured as the proportion of days covered (PDC) while on ADA-adaz. A total of 23,737 patients with an ADA-adaz prescription after July 2023 were included. For patients in the demographics and clinical assessment subgroup, the median age was 49.0 years, 59.4% were female, and 91.0% had commercial insurance. Patients received ADA-adaz mostly for rheumatoid arthritis (33.0%) and Crohn disease (23.2%). Common baseline comorbidities included hyperlipidemia (29.2%), hypertension (29.0%), anxiety (22.8%), and osteoarthritis (21.4%). During baseline, 93.2% of patients received a biologic; 98.2% received the reference ADA, and 83.0% were treated with biologics for at least 6 to 12 months. Other baseline treatments included systemic corticosteroids (52.3%), non-steroidal anti-inflammatory drugs (35.4%), and disease-modifying antirheumatic drugs (34.6%). Of the 1108 (4.7%) patients in the persistence and adherence assessment subgroup, persistence at 3 months was 65.7%, and average PDC was 93.9% while on ADA-adaz. These findings should be interpreted with caution due to limited follow-up availability. In summary, patients who initiated ADA-adaz in the months following its US availability were predominantly commercially insured. The high rate of prior ADA use highlighted a transition to biosimilars in biologic-experienced patients. The end of ADA-adaz persistence was largely driven by switching to other ADA treatments. Among patients with available short-term follow-up, adherence while on ADA-adaz was high. Further studies with longer follow-up can assess ADA-adaz utilization patterns and long-term outcomes.